A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine

Trial Profile

A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 23 May 2018

At a glance

  • Drugs Galcanezumab (Primary)
  • Indications Migraine
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 23 May 2018 Results presented at the 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 08 Sep 2017 According to an Eli Lilly media release, detailed results from this phase 3 study will be presented at the 18th Congress of the International Headache Society
    • 08 Sep 2017 Results published in an Eli Lilly Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top